Mei L. Cheng
Mei L. Cheng publishes mostly in Cardiology and Cardiovascular Medicine, Genetics and Pathology and Forensic Medicine, on topics such as Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment and Heart Failure Treatment and Management.
- World rank
- #670,766 of 7,710,434 ranked researchers
- Rank in United States
- #227,752 of 1,627,098
- Works
- 35
- Citations
- 5.1k
- Citations per work
- 147.0
What does Mei L. Cheng research?
Mei L. Cheng's work is mostly in Medicine (72%), Immunology and Microbiology (8%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences2571.6%
- Medicine2571.6%
- Everything else720.0%
- Life Sciences38.4%
- 1Cardiology and Cardiovascular Medicine24% of their works
- 2Genetics21% of their works
- 3Pathology and Forensic Medicine19% of their works
- 4Immunology8% of their works
- 5Pharmacology4% of their works
- 6Gastroenterology3% of their works
Research topics
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Heart Failure Treatment and Management
- Immunodeficiency and Autoimmune Disorders
- Spine and Intervertebral Disc Pathology
- Musculoskeletal pain and rehabilitation
- Cardiac electrophysiology and arrhythmias
- Cardiac pacing and defibrillation studies
Which keywords describe Mei L. Cheng's research?
The keywords of their largest research topics: Rituximab, Chronic Lymphocytic Leukemia, Genomic Aberrations, Classification, Lymphoma, Epidemiology, Heart Failure and Diagnosis.
- Implantable Cardioverter-Defibrillator
- Arrhythmias
- Intervertebral Disc
- Chronic Pain
- Genetic Mutations
- Low Back Pain
- Diagnosis
- Epidemiology
- Classification
- Chronic Lymphocytic Leukemia
- Rituximab
- Genomic Aberrations
- Lymphoma
- Heart Failure
- Guidelines
- Sudden Cardiac Death
- Primary Immunodeficiency
- Global Burden
- Lumbar Disc Degeneration
- Cardiac Resynchronization Therapy
- Long-QT Syndrome
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 21 words, with their numbers
- Rituximab342 topics
- Chronic Lymphocytic Leukemia201 topic
- Genomic Aberrations201 topic
- Classification141 topic
- Lymphoma141 topic
- Epidemiology122 topics
- Heart Failure112 topics
- Diagnosis81 topic
- Guidelines81 topic
- Low Back Pain82 topics
- Sudden Cardiac Death62 topics
- Genetic Mutations51 topic
- Primary Immunodeficiency51 topic
- Chronic Pain41 topic
- Global Burden41 topic
- Intervertebral Disc41 topic
- Lumbar Disc Degeneration41 topic
- Arrhythmias31 topic
- Cardiac Resynchronization Therapy31 topic
- Implantable Cardioverter-Defibrillator31 topic
- Long-QT Syndrome31 topic
Where does Mei L. Cheng work?
Mei L. Cheng's main affiliation in the publication record is Pharmacyclics (United States), United States.
How many publications and citations does Mei L. Cheng have?
OpenAlex counts 35 works and 5,144 citations for Mei L. Cheng, an h-index of 18, ranking #670,766 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Mei L. Cheng. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.